Floragenex, Inc.

Floragenex, Inc. specializes in genomic technologies, providing advanced sequencing services to academic, government, and commercial institutions globally, facilitating in-depth genetic analysis and insights. Founded in 2007 in Portland, US, Floragenex, Inc. focuses on genomic analysis and has consistently evolved its service offerings to meet the needs of its diverse client base.

The company’s founder has a history of engagement in the genomics field, contributing to its established presence in the market. Floragenex specializes in genomic technologies and analysis, offering a range of services for academic, government, and commercial institutions worldwide. Their core product offerings include various sequencing services such as Restriction site-associated DNA sequencing (RAD-Seq), double digest RAD sequencing, whole genome sequencing (WGS), and RNA sequencing (RNA-Seq). These services are designed to analyze genetic information, enabling users to identify genetic variants, assess gene expression, and explore methylated sites within genomes.

With nearly two decades of experience, Floragenex has partnered with numerous institutions, generating valuable genomic data that supports a wide array of research initiatives. The company serves a global client base, including universities, research institutes, and biotech firms, focusing on North America, Europe, and select markets in Asia. Floragenex operates on a B2B transaction model, primarily engaging with academic and research institutions as clients. The company generates revenue through service contracts for its sequencing technologies, typically structured as project-based agreements.

Clients collaborate with Floragenex to submit samples, which are then sequenced and analyzed. The pricing structure is tailored to the specific needs of each project, reflecting the complexity and scope of the sequencing services rendered. Floragenex's flagship offerings, such as whole genome sequencing and RNA-Seq, are integral to research projects, ensuring that clients receive critical genetic insights necessary for their scientific inquiries. The company’s revenue streams are bolstered by longstanding relationships with key partners in the genomics field, facilitating continued growth and investment in innovative sequencing technologies.

Floragenex aims to expand its product line with new genomic analysis tools set to launch in the next year. The company is also targeting expansion into regions including Asia and Europe by 2025. Recent funding will be strategically utilized to enhance its technological capabilities and broaden market outreach, ensuring that its sequenced data services continue to meet the evolving needs of the scientific community.